Featured Content

Thomas Marsland, MD
Vice President Integrated Community Oncology Network Former Community Representative ASCO Board of Directors

ASCO Resolutions Supported by AMA House of Delegates

(ASCO in Action) June 17, 2016 - At the American Medical Association’s (AMA) annual House of Delegates meeting, delegates approved four resolutions submitted by ASCO, demonstrating the entire medical community’s commitment to key cancer care priorities.

Commentary: As one of ASCO's representatives to AMA I really enjoyed the meeting. ASCO indeed had a banner meeting presenting...

OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev

(BMS) June 30, 2016 - Bristol-Myers Squibb Company and PsiOxus Therapeutics, Ltd. today announced an exclusive clinical collaboration agreement to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ enadenotucirev, a systemically administered oncolytic adenovirus therapeutic, in combination with Bristol-Myers Squibb’s Immuno-Oncology (I-O) agent Opdivo (nivolumab) to treat a range of tumor types in late-stage cancer patients.
read corporate press release »

NAPOLI-1 Data Demonstrates ONIVYDE(R) Regimen Maintains Quality of Life While Improving Overall Survival in Patients with Metastatic Pancreatic Cancer

(Merrimack) June 30, 2016 - Merrimack Pharmaceuticals, Inc. today announced a newly presented analysis of the Phase 3 NAPOLI-1 data shows patients treated with ONIVYDE® (irinotecan liposome injection), also known as "nal-IRI," in combination with fluorouracil (5-FU) and leucovorin, maintain similar baseline quality of life at 12 weeks despite the addition of a second chemotherapeutic agent when compared to 5-FU and leucovorin alone.
read corporate press release »

New Ovarian Cancer Drugs Raise Hope — But Not For All

(STAT) June 30, 2016 - Promising new therapies are springing up to treat ovarian cancer, long one of the most deadly and hard to treat malignancies.
read article »


View ALL News »

News Story Commentary By Academic and Community Oncologists

ASCO Resolutions Supported by AMA House of Delegates (ASCO in Action)

As one of ASCO's representatives to AMA I really enjoyed the meeting. ASCO indeed had a banner meeting presenting...posted by: Thomas Marsland, MD

After Negative PET, Drop Bleomycin in Hodgkin's Lymphoma (Medscape Medical News)

This study is a game changer in providing data that supports stopping bleomycin in patients who are PET negative...posted by: William, Harwin MD

Protection From Trastuzumab Cardiotoxicity in Breast Cancer (Medscape Medical News)

This sobering report shows that angiotensin blockade, long postulated to protect the heart from trastuzumab-related...posted by: Debu, Tripathy, MD

Prostate Cancer Treatment Could Work In Half The Time And Without Gruelling Side Effects, 14-Year Study Finds (The Telegraph [UK])

Lancet Oncology has just published two articles on (moderate) hypofractionation for prostate cancer that suggest...posted by: Howard Sandler, MD, MS, FASTRO

Supreme Court’s Ruling In Patent Case A Blow To Drug Industry (STAT)

This ruling will open the doors a bit wider for generics and, perhaps, biosimilars as well.posted by: Dean Gesme, MD

OBR Training

Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.

OBR Job Board

Navigating Cancer has 1 job posted.

Bayer Pharmaceuticals has 1 job posted.

Touchpoint Solutions has over 20 jobs posted.

Check out the OBR Job Board here.

The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™

View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.


Symbol  %Δ
TTHI +110.00%
GALE +34.29%
CASI +12.97%
CLVS -12.05%
SRNE -7.90%
NYMX -6.21%


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results

Date: June 2016
Company: CytRx Corp.
Product: aldoxorubicin

Date: Q2 2016
Company: Galena Biopharma
Product: NeuVax™ (nelipepimut-S)

Date: Q2 2016
Company: Cyclical Pharmaceuticals
Product: sapacitibine

See All OBR Radar items»